Wegovy vs Mounjaro: Weight Management Meets Diabetes Treatment

One is FDA-approved for obesity, the other for diabetes — yet both are widely used for weight loss. How do semaglutide and tirzepatide stack up?

Take the Free Quiz

Free consultation · No commitment · Results in weeks

Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Wegovy vs Mounjaro is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated March 2026Medically reviewed by licensed providers

Wegovy vs Mounjaro: both are FDA-approved GLP-1 medications for weight loss. Wegovy (semaglutide) and Mounjaro (tirzepatide) differ in mechanism and clinical efficacy. Weight Method offers both from $297/month with virtual consultations and licensed providers.

Overview

Wegovy (semaglutide 2.4 mg, Novo Nordisk) and Mounjaro (tirzepatide up to 15 mg, Eli Lilly) are frequently compared because both produce substantial weight loss despite having different FDA-approved indications. Wegovy is approved for chronic weight management (2021), while Mounjaro is approved for type 2 diabetes (2022) but routinely prescribed off-label for weight loss due to its exceptional body weight reduction data. They represent the two dominant GLP-1 platforms — single-receptor semaglutide versus dual-receptor tirzepatide.

Key Fact

Wegovy (semaglutide 2.4mg) is FDA-approved for weight management with 15-17% average weight loss and a proven 20% cardiovascular risk reduction (SELECT trial). Mounjaro (tirzepatide 15mg) is approved for diabetes but shows 15-21% weight loss — matching or exceeding Wegovy despite a diabetes indication.

Source: STEP trials (NEJM 2021); SELECT Trial (NEJM 2023); SURPASS trials (NEJM 2021-2022)

Wegovy

ManufacturerNovo Nordisk
Active Ingredientsemaglutide
FDA IndicationChronic weight management
FDA Approval2021
FormulationInjectable pen
FrequencyOnce weekly
Available Doses0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg
Avg. Weight Loss15-17%
Our Price$297/mo

Mounjaro

ManufacturerEli Lilly
Active Ingredienttirzepatide
FDA IndicationType 2 diabetes
FDA Approval2022
FormulationInjectable pen
FrequencyOnce weekly
Available Doses2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
Avg. Weight Loss15-21%
Our Price$349/mo

Key Differences

Mounjaro's diabetes trials showed weight loss (15-21%) that rivals Wegovy's dedicated obesity trial results (15-17%), and its weight management sibling Zepbound pushed even higher (20-25%). This makes Mounjaro particularly attractive for off-label weight loss prescribing. Wegovy's advantage is its specific FDA approval for weight management and completed cardiovascular outcome data (the SELECT trial showing 20% cardiac event reduction). Through Weight Method, semaglutide is $297/mo and tirzepatide is $349/mo.

Verdict

For patients without diabetes whose primary goal is weight loss, Wegovy offers a purpose-built, FDA-approved solution with cardiovascular benefits data. Mounjaro is the stronger pick for patients with type 2 diabetes who want maximum weight reduction, or those willing to pay a premium for tirzepatide's dual-action mechanism. Consult with your Weight Method provider to determine which aligns with your health profile.

Ready to Get Started?

Answer a few quick questions to see if you qualify for GLP-1 medication.

Check Eligibility

Your Treatment Options

Clinically proven GLP-1 medications at transparent prices

Starting at$297/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Same active ingredient as Ozempic® & Wegovy®. Proven to reduce body weight by up to 15%.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Same active ingredient as Mounjaro® & Zepbound®. Dual-action GLP-1/GIP for enhanced results.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Clinical data suggests yes — Mounjaro's trials showed 15-21% weight loss even in diabetes patients, matching or exceeding Wegovy's 15-17% in dedicated obesity trials. At their highest doses, tirzepatide (Mounjaro's ingredient) consistently outperforms semaglutide (Wegovy's ingredient) for weight reduction.

Mounjaro is FDA-approved only for type 2 diabetes, but doctors frequently prescribe it off-label for weight loss. Its weight-loss-specific sibling (Zepbound) has the formal obesity indication. Through Weight Method, your provider will evaluate your profile and prescribe the most appropriate medication.

Wegovy currently has stronger cardiovascular evidence — the SELECT trial demonstrated a 20% reduction in major adverse cardiac events in overweight/obese adults. Mounjaro's cardiovascular outcome trials are still in progress. If heart health is a primary concern, this data favors Wegovy.

Both cause similar gastrointestinal side effects: nausea, vomiting, diarrhea, constipation, and decreased appetite. These are most common during dose titration and typically improve over 4-8 weeks. Neither medication has shown significantly worse tolerability than the other in comparative analyses.

Through Weight Method, compounded semaglutide (Wegovy's active ingredient) is $297/mo while compounded tirzepatide (Mounjaro's active ingredient) is $349/mo — a $52/month difference. At retail pharmacies, both medications exceed $1,000/month without insurance, with Mounjaro typically listing slightly higher.

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.

Related Brand Pages

Wegovy HubWegovy Side EffectsWegovy ResultsWegovy DosingMounjaro HubMounjaro Side EffectsMounjaro ResultsMounjaro Dosing

More Comparisons

Ozempic vs WegovyMounjaro vs ZepboundRybelsus vs Oral-wegovyOzempic vs MounjaroWegovy vs ZepboundOzempic vs Zepbound